thalidomide has been researched along with docetaxel anhydrous in 29 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 17 (58.62) | 29.6817 |
| 2010's | 11 (37.93) | 24.3611 |
| 2020's | 1 (3.45) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chalas, E; Hindenburg, A; Jeyakumar, A | 1 |
| Arlen, P; Dahut, WL; Fedenko, K; Fernandez, P; Figg, WD; Gulley, J; Hamilton, M; Kruger, EA; Noone, M; Parker, C; Pluda, J | 1 |
| Remlinger, KA | 1 |
| Arlen, P; Dahut, WL; Figg, WD; Gulley, J; Horne, MK; Lakhani, N; Parker, C; Parnes, H | 1 |
| Klem, J; Price, N; Reddy, K; Tyagi, P | 1 |
| Arlen, PM; Cox, MC; Dahut, W; Figg, WD; Gulley, J; Linehan, WM | 1 |
| Arlen, PM; Chen, CC; Dahut, WL; Fedenko, KM; Figg, WD; Gulley, JL; Jones, E; Linehan, WM; Liu, Y; Parker, CE; Parnes, H; Steinberg, SM; Wright, JJ | 1 |
| Arné-Bès, MC | 1 |
| Lopes, G; Rocha Lima, CM | 1 |
| Figg, WD | 1 |
| Borden, E; Bukowski, R; Cline-Burkhardt, M; Davis, M; Dowlati, A; Dreicer, R; Kalmadi, S; Mekhail, T; O'Keefe, S; Pelley, RJ | 1 |
| Autorino, R; De Laurentiis, M; De Placido, S; Di Lorenzo, G; Forestieri, V; Giugliano, F; Imbimbo, C; Mirone, V; Prudente, A; Romano, C | 1 |
| Arlen, P; Chen, C; Dahut, W; Fedenko, K; Figg, WD; Gulley, JL; Jones, E; Latham, L; Li, H; Parnes, H; Retter, A; Sissung, T; Steinberg, SM; Wright, JJ; Wu, S | 1 |
| Bertolini, F; Figg, WD; Li, H; Price, DK; Raia, V | 1 |
| Aragon-Ching, J; Baum, CE; Dahut, W; Deeken, J; Figg, WD; Price, DK; Sissung, TM; Sparreboom, A; Steinberg, SM | 1 |
| Bako, J; Bokar, JA; Brell, JM; Cooney, MM; Dowlati, A; Gibbons, J; Horvath, N; Krishnamurthi, S; Nock, C; Remick, SC; Sanborn, SL | 1 |
| Dahut, WL; Figg, WD; Ning, YM | 1 |
| Cormier, T; Dahut, WL; Deeken, JF; Figg, WD; Liewehr, DJ; Miao, X; Price, DK; Sissung, TM; Steinberg, SM; Tran, K | 1 |
| Arlen, PM; Chen, CC; Dahut, WL; Figg, WD; Gulley, JL; Jones, E; Kim, YS; Latham, L; Lee, MJ; Madan, RA; Ning, YM; Parnes, HL; Steinberg, SM; Sun, H; Trepel, JB; Woo, S; Wright, JJ | 1 |
| Rexer, H | 1 |
| Adams, M; Bartlett, JB; Dalgleish, AG; Galustian, C; Henry, JY; Lu, L; Meyer, B | 1 |
| Attarian, H; Ghadyani, M; Haghighi, S; Rezvani, H | 1 |
| Chen, L; Qiu, X; Wang, R; Xie, X | 1 |
| Barton, D; Bellmunt, J; Budnik, N; Burke, JM; Choudhury, A; de Olza, MO; de Wit, R; Doner, K; Fandi, A; Fizazi, K; Flechon, A; Gschwend, JE; Houede, N; Jungnelius, U; Kopyltsov, E; Li, S; Petrylak, DP; Sternberg, CN; Van As, N; Vogelzang, NJ; Wiechno, PJ | 1 |
| Barton, D; Bellmunt, J; Berry, WR; Burke, JM; Crane, E; De Wit, R; Doner, K; Fandi, A; Fizazi, K; Gandhi, A; Hainsworth, JD; Hutson, TE; Jungnelius, U; Liu, K; Petrylak, DP; Sternberg, CN; Vogelzang, NJ; Waldman, MF; Wiechno, PJ | 1 |
| Barton, D; Bellmunt, J; Budnik, N; Burke, JM; Choudhury, A; de Morrée, ES; de Wit, R; Doner, K; Fandi, A; Flechon, A; Gschwend, JE; Houede, N; Jungnelius, U; Kopyltsov, E; Li, JS; Li, S; Ochoa de Olza, M; Petrylak, DP; Sternberg, CN; van As, N; Vogelzang, NJ; Wiechno, PJ | 1 |
| Ao, M; Ao, Y; Xiao, X | 1 |
| Cao, C; Chen, W; Hu, J; Shi, Y; Wang, L; Ye, W; Zhou, L; Zhou, W | 1 |
5 review(s) available for thalidomide and docetaxel anhydrous
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Cutaneous reactions to chemotherapy drugs: the art of consultation.
Topics: Animals; Antineoplastic Agents; Bleomycin; Docetaxel; Doxorubicin; Drug Eruptions; Humans; Hydroxyurea; Paclitaxel; Skin; Taxoids; Thalidomide | 2003 |
[Neurotoxic effects of medications: an update].
Topics: Anti-Retroviral Agents; Antineoplastic Agents; Carboplatin; Cisplatin; Colchicine; Docetaxel; Humans; Interferon-alpha; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Peripheral Nervous System Diseases; Taxoids; Thalidomide | 2004 |
Docetaxel in the management of advanced pancreatic cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carboplatin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Humans; Irinotecan; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Taxoids; Thalidomide | 2005 |
The efficacy and safety of docetaxel plus thalidomide vs. docetaxel alone in patients with androgen-independent prostate cancer: a systematic review.
Topics: Androgens; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Prostatic Neoplasms; Taxoids; Thalidomide; Treatment Outcome | 2014 |
12 trial(s) available for thalidomide and docetaxel anhydrous
| Article | Year |
|---|---|
A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer.
Topics: Adenocarcinoma; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Docetaxel; Humans; Male; Middle Aged; Paclitaxel; Prostatic Neoplasms; Taxoids; Thalidomide | 2001 |
Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Humans; Infusions, Intravenous; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Thalidomide; Treatment Outcome | 2004 |
Phase I trial of three-weekly docetaxel, carboplatin and oral lenalidomide (Revlimid) in patients with advanced solid tumors.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Taxoids; Thalidomide; Treatment Outcome | 2007 |
Thalidomide in combination with oral daily cyclophosphamide in patients with pretreated hormone refractory prostate cancer: a phase I clinical trial.
Topics: Administration, Oral; Aged; Androgens; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Docetaxel; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Thalidomide; Treatment Outcome | 2007 |
Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer.
Topics: Aged; Androgens; Animals; Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP1B1; Cytochrome P-450 Enzyme System; Docetaxel; Estramustine; Genotype; Humans; Male; Mice; Mice, Nude; Middle Aged; Prostatic Neoplasms; Survival Analysis; Taxoids; Thalidomide; Treatment Outcome | 2007 |
Phase I trial of docetaxel given every 3 weeks and daily lenalidomide in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Prognosis; Taxoids; Thalidomide; Treatment Outcome; Young Adult | 2009 |
A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform.
Topics: Adult; Aged; Carbohydrate Sulfotransferases; Docetaxel; Humans; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Orchiectomy; Pharmacogenetics; Polymorphism, Single Nucleotide; PPAR delta; Prostatic Neoplasms; Sulfotransferases; Taxoids; Thalidomide | 2010 |
Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cell Line, Tumor; Disease-Free Survival; Docetaxel; Down-Regulation; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Mice; Mice, SCID; Middle Aged; Orchiectomy; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Thalidomide; Time Factors; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays | 2010 |
Efficacy of taxotere, thalidomide, and prednisolone in patients with hormone-resistant metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Gonadotropin-Releasing Hormone; Humans; Kaplan-Meier Estimate; Male; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms; Soft Tissue Neoplasms; Taxoids; Thalidomide | 2012 |
Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Placebos; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids; Thalidomide | 2015 |
Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Lenalidomide; Male; Neoplastic Cells, Circulating; Prednisone; Prognosis; Prostatic Neoplasms, Castration-Resistant; Survival Analysis; Taxoids; Thalidomide | 2017 |
Association of Survival Benefit With Docetaxel in Prostate Cancer and Total Number of Cycles Administered: A Post Hoc Analysis of the Mainsail Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids; Thalidomide | 2017 |
12 other study(ies) available for thalidomide and docetaxel anhydrous
| Article | Year |
|---|---|
Sustained complete remission in a patient with platinum-resistant ovarian yolk sac tumor.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Endodermal Sinus Tumor; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Taxoids; Thalidomide | 2001 |
Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Middle Aged; Paclitaxel; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Retrospective Studies; Taxoids; Thalidomide; Venous Thrombosis | 2003 |
Highlights from the XII European Cancer Conference Copenhagen, Denmark.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Male; Mitoxantrone; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids; Thalidomide; Tomography, Emission-Computed | 2003 |
National Cancer Institute intramural approach to advanced prostate cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Biomedical Research; Cancer Vaccines; Clinical Trials as Topic; Docetaxel; Humans; Ketoconazole; Male; National Institutes of Health (U.S.); Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Thalidomide; United States | 2002 |
The 2005 Leon I. Goldberg Young Investigator Award Lecture: Development of thalidomide as an angiogenesis inhibitor for the treatment of androgen-independent prostate cancer.
Topics: Androgens; Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Docetaxel; Humans; Male; Neovascularization, Pathologic; Prostatic Neoplasms; Taxoids; Thalidomide | 2006 |
Circulating endothelial cells as a therapeutic marker for thalidomide in combined therapy with chemotherapy drugs in a human prostate cancer model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Synergism; Endothelial Cells; Estramustine; Humans; Male; Mice; Mice, SCID; Neoplasm Transplantation; Prostatic Neoplasms; Random Allocation; Stem Cells; Taxoids; Thalidomide; Transplantation, Heterologous | 2008 |
ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel.
Topics: Androgens; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Docetaxel; Drug Resistance, Neoplasm; Gene Frequency; Genotype; Humans; Kaplan-Meier Estimate; Male; Polymerase Chain Reaction; Polymorphism, Genetic; Prostatic Neoplasms; Taxoids; Thalidomide | 2008 |
Reversal of docetaxel resistance with bevacizumab and thalidomide.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Neoplasm Metastasis; Orchiectomy; Prostatic Neoplasms; Taxoids; Thalidomide | 2009 |
[Study to castrate-resistant prostate cancer: AUO study AP 60/10].
Topics: Antineoplastic Combined Chemotherapy Protocols; Castration; Clinical Trials as Topic; Docetaxel; Humans; Lenalidomide; Male; Prednisone; Prostatic Neoplasms; Taxoids; Thalidomide; Treatment Failure | 2011 |
Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Docetaxel; Drug Synergism; Drug Therapy, Combination; Humans; In Vitro Techniques; Lenalidomide; Male; Mice; Mice, Nude; Prostatic Neoplasms; Taxoids; Thalidomide; Treatment Outcome; Xenograft Model Antitumor Assays | 2012 |
Low density lipoprotein modified silica nanoparticles loaded with docetaxel and thalidomide for effective chemotherapy of liver cancer.
Topics: Animals; Antineoplastic Agents; Docetaxel; Drug Synergism; Hep G2 Cells; Humans; Lipoproteins, LDL; Liver Neoplasms, Experimental; Male; Mice; Nanoparticles; Silicon Dioxide; Taxoids; Thalidomide; Time Factors | 2018 |
Design and synthesis of α-naphthoflavone chimera derivatives able to eliminate cytochrome P450 (CYP)1B1-mediated drug resistance via targeted CYP1B1 degradation.
Topics: Benzoflavones; Cell Line, Tumor; Cytochrome P-450 CYP1B1; Docetaxel; Drug Design; Drug Resistance, Neoplasm; Humans; Proteolysis; Thalidomide | 2020 |